DelveInsight Blog
Map the latest in Pharmaceutical, Healthcare, Medical Devices and Biotech Space with DelveInsight’s panoramic market analysis while the Pharma Industry continues to rapidly evolve with several approvals,failures, acquisitions, and partnerships teeing up the domain.
The Silent Victory: Athira Pharma’s Quest Against Alzheimer’s
Athira Pharma presented a poster titled “Targeting Neurotrophic HGF Signaling for the Treatment of Neurodegenerative Disorders” at the recently, concluded American Academy of Neurology 2024 Annual Meeting, held in Denver, Colorado. It highlighted preclinical data supporting the development of Athira's pipeline of small molecule candidates targeting the neurotrophic hepatocyte growth factor (HGF) system, including fosgonimeton for Alzheimer’s disease, ATH-1105 for amyotrophic lateral sclerosis (ALS), and ATH-1020 for Parkinson’s disease. The current treatment regime for Alzheimer’s is mostly symptomatic with only one approved disease-modifying therapy, which is also marred with safety…
Semaglutide: Unveiling Hope for Alzheimer’s Disease Patients
Semaglutide provides a potential therapeutic avenue for aging-related neurodegenerative diseases, such as Alzheimer's disease through enhanced brain glucose metabolism. The comparable safety data presented by Novo Nordisk strengthens Semaglutide’s profile as a potential candidate in the early Alzheimer’s Disease market and provides the much-needed impetus as a treatment to slow the disease progression. According to studies, having diabetes at the age of 55 increases the likelihood of acquiring dementia and Alzheimer's disease due to an increased risk of brain artery damage. Semaglutide, a long-acting glucagon-like peptide-1 receptor agonist, mimics the…
Prothena’s Promise: Revolutionizing Alzheimer’s Treatment with a Breakthrough Therapy
PRX012, a next-generation subcutaneous antibody, has the potential to eliminate treatment obstacles due to its unique pharmacological properties and improved binding profile compared to conventional amyloid-beta targeting medicines. PRX123, targeting the hallmarks of Alzheimer’s, Aβ plaque, and tau tangles, has the potential to revolutionize the treatment regime, and offers a beacon of hope for Alzheimer’s prevention. The Alzheimer's drugs market has made significant progress, especially in the last half-decade, with more amyloid beta-protein-targeted monoclonal antibodies entering the market space. With the evolving paradigm of “amyloid hypothesis”, there are many hopes…
-Agonist.png "Toll-like Receptors Agonist")
